In a recent update, Adverum Biotechnologies (ADVM, Financial) has received a maintained "Buy" rating from Chardan Capital. Lead analyst Daniil Gataulin reaffirmed the company's price target at $33.00 USD. The price target remains consistent with the previous set value, indicating no change in the financial outlook from the prior assessment.
Chardan Capital's analysis continues to reflect confidence in Adverum Biotechnologies (ADVM, Financial), as their maintained "Buy" rating suggests optimism about the company's market performance. This rating reflects Chardan Capital's expectation that ADVM will perform well relative to the broader market.
The unchanged price target of $33.00 USD demonstrates a steady projection for Adverum Biotechnologies (ADVM, Financial), with expectations set by Chardan Capital remaining stable. As of the report date on May 15, 2025, Adverum Biotechnologies is trading on the NASDAQ exchange.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Adverum Biotechnologies Inc (ADVM, Financial) is $21.25 with a high estimate of $33.00 and a low estimate of $4.00. The average target implies an upside of 1,030.32% from the current price of $1.88. More detailed estimate data can be found on the Adverum Biotechnologies Inc (ADVM) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Adverum Biotechnologies Inc's (ADVM, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
